Literature DB >> 10520974

Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.

H G Nurnberg1, P M Thompson, P L Hensley.   

Abstract

BACKGROUND: This investigation focuses on the 3 most frequently used selective serotonin reuptake inhibitors (SSRIs) (paroxetine, fluoxetine, sertraline) and examines the rate of medication switches as a measure of effectiveness. We answer 2 questions: (1) What is the likelihood that a patient starting treatment with an SSRI will complete treatment with the same agent? and (2) Depending on the initial SSRI agent used, do patients switch at different frequencies?
METHOD: A retrospective chart review was performed on 2779 patients treated in a university outpatient clinic from March 1995 to January 1997. Of these, 263 patients given antidepressants were randomly selected: 214 were prescribed SSRIs; 24, novel antidepressants; and 25, tricyclic antidepressants.
RESULTS: There was no significant difference in rate of switching between the different classes of antidepressant (p = .1) nor between drugs within the SSRI class (p = .513). When medication change was the independent factor, significant differences between the groups were total time in treatment and number of visits (p < .001 and p = .011, respectively). Age, education, and Clinical Global Impressions-Severity of Illness scale scores (admission, discharge, and change) were not significantly different between the groups.
CONCLUSION: Approximately 25% of patients started with an SSRI will switch to another antidepressant in the course of their treatment. The SSRIs appear to be equivalent in effectiveness. They are not interchangeable, because patients who discontinue one SSRI for lack of tolerability or response can generally be treated effectively with another.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520974     DOI: 10.4088/jcp.v60n0902

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features.

Authors:  Patricia A. Marken; J Stuart Munro
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-12

2.  Metabolic mapping of the effects of the antidepressant fluoxetine on the brains of congenitally helpless rats.

Authors:  Jason Shumake; Rene A Colorado; Douglas W Barrett; F Gonzalez-Lima
Journal:  Brain Res       Date:  2010-05-12       Impact factor: 3.252

Review 3.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 4.  Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls.

Authors:  P L Hensley; H G Nurnberg
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  Prioritization and evaluation of depression candidate genes by combining multidimensional data resources.

Authors:  Chung-Feng Kao; Yu-Sheng Fang; Zhongming Zhao; Po-Hsiu Kuo
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

6.  Thermodynamics of selective serotonin reuptake inhibitors partitioning into 1,2-dioleoyl-sn-glycero-3-phosphocholine bilayers.

Authors:  Dat T N Ngo; Trinh Q Nguyen; Hieu K Huynh; Trang T Nguyen
Journal:  RSC Adv       Date:  2020-10-27       Impact factor: 4.036

7.  Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients.

Authors:  Karel Kostev; Juliana Rex; Thilo Eith; Christina Heilmaier
Journal:  Ger Med Sci       Date:  2014-10-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.